Enasidenib for Liver Disease

"The Celgene-sponsored trial has a main objective of assessing the pharmacokinetics (AUC0-t) of CC-90007 over an extended period. Supplementary objectives include quantifying AUC0–t, AUC 0–∞, and Tmax for AGI-16903."

"Presently, 24 live experiments for Enasidenib are taking place in 28 countries and 84 cities. Celgene initiated the first study of their drug back in 2013 with a total of 345 participants who completed Phase 1 & 2 trials successfully. Since then, 6 additional research projects have been launched."

"The safety of Enasidenib is rated at 1 given the limited information available from Phase I studies, which indicate potential efficacy but lack comprehensive data on its security."

"The requirements for inclusion in this trial are hepatic impairment and a patient aged between 40 and 75 years-old. Currently, up to 48 patients will be accepted into the study."

"This scientific trial is open to those who are between the ages of 40 and 75."

"As of 2013, enasidenib has been the subject of 6 completed trials. At present, there are 24 studies in progress, with a considerable number taking place in Miami, Florida."

"Affirmative, the clinicaltrials.gov record indicates that this research endeavor is currently enrolling members. It was initially published on November 13th 2020 and its information has been recently revised on November 7th 2022. The project requires a total of 48 individuals to be recruited from 3 separate locations."

"As indicated on clinicaltrials.gov, the team behind this medical study is actively seeking volunteers. The trial was originally announced on November 13th 2020 and its most recent update occurred seven months later in July 2022."